By contrast, we have shown that rosiglitazone (this study) as well as the PDGFR tyrosine kinase inhibitor Gleevec [1] are highly potent in protecting smLRP− mice from atherosclerosis. This evidence concerns the gene PDGFRB and atherosclerosis.